The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
 
Romualdo Barroso-Sousa
No Relationships to Disclose
 
Hao Guo
No Relationships to Disclose
 
William Thomas Barry
Research Funding - Pfizer (Inst)
Other Relationship - ARMO BioSciences
 
Arlindo R. Ferreira
No Relationships to Disclose
 
Rebecca Rees
No Relationships to Disclose
 
Eric P. Winer
Honoraria - Genentech/Roche; Lilly; Tesaro
Consulting or Advisory Role - InfiniteMD; Leap Therapeutics
Research Funding - Genentech (Inst)
 
Nikhil Wagle
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Novartis
Research Funding - Merck; Novartis
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; Genentech; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
Research Funding - Bristol-Myers Squibb; Eisai; Eisai; Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)